Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - bimzelx
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp28d78e4ecee5ce96f67160a74729d480
identifier: http://ema.europa.eu/identifier
/EU/1/21/1575/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Bimzelx 160 mg solution for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-28d78e4ecee5ce96f67160a74729d480
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/21/1575/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - bimzelx
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
Instructions for use
What is in this leaflet
What Bimzelx is Bimzelx contains the active substance bimekizumab.
What Bimzelx is used for Bimzelx is used to treat the following inflammatory diseases:
Plaque psoriasis
Bimzelx is used in adults to treat a skin condition called plaque psoriasis. Bimzelx reduces the symptoms, including pain, itching, and scaling of the skin.
Psoriatic arthritis Bimzelx is used to treat adults with psoriatic arthritis. Psoriatic arthritis is a disease that causes inflamed joints, often accompanied by plaque psoriasis. If you have active psoriatic arthritis, you may first be given other medicines. If these medicines do not work well enough or in case of intolerance, you will be given Bimzelx either alone or in combination with another medicine called methotrexate.
Bimzelx reduces inflammation and can therefore help to reduce pain, stiffness, swelling in and around your joints, psoriatic skin rash, psoriatic nail damage and slow down the damage to the cartilage and bone of the joints involved in the disease. These effects can help you to control signs and symptoms of the disease, ease your normal daily activities, reduce tiredness, and improve your quality of life.
Axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing spondylitis (radiographic axial spondyloarthritis) Bimzelx is used to treat adults with an inflammatory disease primarily affecting the spine which causes inflammation of the spinal joints, called axial spondyloarthritis. If the condition is not visible using X-rays, it is referred to as non-radiographic axial spondyloarthritis ; if it occurs in patients with visible signs on X-rays, it is referred to as ankylosing spondylitis or radiographic axial spondyloarthritis .
If you have axial spondyloarthritis you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Bimzelx to reduce the signs and symptoms of the disease, reduce inflammation and improve your physical function. Bimzelx can help to reduce back pain, stiffness and tiredness, which can ease your normal daily activities and improve your quality of life.
How Bimzelx works Bimekizumab, the active substance in Bimzelx, belongs to a group of medicines called interleukin (IL) inhibitors. Bimekizumab works by reducing the activity of two proteins called IL-17A and IL-17F, which are involved in causing inflammation. There are higher levels of these proteins in inflammatory diseases such as psoriasis, psoriatic arthritis and axial spondyloarthritis.
Do not use Bimzelx
Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Bimzelx if:
Inflammatory bowel disease (Crohn s disease or ulcerative colitis) Stop using Bimzelx and tell your doctor or get medical help immediately if you notice blood in the stool, abdominal cramps, pain, diarrhoea or weight loss. These may be signs of new or worsening inflammatory bowel disease (Crohn s disease or ulcerative colitis).
Look out for infections and allergic reactions Bimzelx can rarely cause serious infections. Talk to your doctor or get medical help immediately if you notice any signs of a serious infection. Such signs are listed under Serious side effects in section 4. Bimzelx can potentially cause serious allergic reactions. Talk to your doctor or get medical help immediately if you notice any signs of a serious allergic reaction. Such signs may include:
Children and adolescents Do not give this medicine to children and young people under 18 years of age. This is because it has not been studied in this age group. Other medicines and Bimzelx Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Pregnancy, breast-feeding and fertility If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. It is preferable to avoid the use of Bimzelx in pregnancy. This is because it is not known how this medicine will affect the baby.
If you are a woman who can become pregnant, you should use contraception while using this medicine and for at least 17 weeks after your last dose of Bimzelx.
If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine. You and your doctor should decide if you can breast-feed or use Bimzelx.
Driving and using machines Bimzelx is unlikely to affect your ability to drive and use machines.
Bimzelx contains sodium This medicine contains less than 1 mmol (23 mg) sodium per dose, that is to say essentially sodium free .
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
How much Bimzelx is given and for how long
Plaque psoriasis The recommended dose, given as injections under your skin ( subcutaneous injections ) is as follows:
Axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing spondylitis (radiographic axial spondyloarthritis) The recommended dose, given as an injection under your skin ( subcutaneous injections ) is 160 mg (given as one pre-filled syringe) every 4 weeks.
You and your doctor or nurse will decide if you should inject this medicine yourself. Do not inject this medicine unless you have been trained by a healthcare professional. A caregiver may also give your injections after they have been trained.
Read the Instructions for use at the end of this leaflet before injecting Bimzelx pre-filled syringe yourself.
If you use more Bimzelx than you should Tell your doctor if you have used more Bimzelx than you should or if you have injected your dose earlier than you should.
If you forget to use Bimzelx Talk to your doctor if you have forgotten to inject a dose of Bimzelx.
If you stop using Bimzelx Talk to your doctor before you stop using Bimzelx. If you stop treatment, your symptoms may come back.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects Tell your doctor or get medical help immediately if you get any of the following side effects:
Possible serious infection - the signs may include:
Your doctor will decide if you can keep using Bimzelx.
Other side effects Tell your doctor, pharmacist or nurse if you get any of the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator between 2 C and 8 C. Do not freeze.
Keep the pre-filled syringes in the original carton in order to protect from light.
Bimzelx can be kept out of the refrigerator for up to 25 days. This must be in the outer carton, not above 25 C and away from direct light. Do not use the pre-filled syringes after this time period. There is a space on the box so you can write the date it was taken out of the refrigerator.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Bimzelx contains
What Bimzelx looks like and contents of the pack Bimzelx is a clear to slightly opalescent liquid. Its colour may vary from colourless to pale brownish- yellow. It comes in a single use disposable pre-filled syringe with needle cap.
Bimzelx is available in unit packs containing 1 or 2 pre-filled syringe(s) and in multipacks comprising 3 cartons, each containing 1 pre-filled syringe, or in multipacks comprising 2 cartons, each containing 2 pre-filled syringes.
Not all pack sizes may be marketed.
Marketing Authorisation Holder UCB Pharma S.A. All e de la Recherche B-1070 Bruxelles, Belgium
Manufacturer UCB Pharma S.A. Chemin du Foriest B-1420 Braine-l Alleud, Belgium
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien UCB Pharma S.A./NV
T l/Tel: + 32 / (0)2 559 92 Lietuva UCB Pharma Oy Finland
Tel: + 358 9 2514 4221 (Suomija)
Te .: + 359 (0) 2 962 30 Luxembourg/Luxemburg UCB Pharma S.A./NV
T l/Tel: + 32 / (0)2 559 92 00 (Belgique/Belgien)
esk republika UCB s.r.o.
Tel: + 420 221 773 Magyarorsz g UCB Magyarorsz g Kft.
Tel.: + 36-(1) 391 0Danmark UCB Nordic A/S
Tlf: + 45 / 32 462 Malta Pharmasud Ltd.
Tel: + 356 / 21 37 64 Deutschland UCB Pharma GmbH
Tel: + 49 /(0) 2173 48 4Nederland UCB Pharma B.V.
Tel.: + 31 / (0)76-573 11 Eesti UCB Pharma Oy Finland
Tel: + 358 9 2514 4221 (Soome)
Norge UCB Nordic A/S
Tlf: + 47 / 67 16 5
UCB . .
: + 30 / 2109974 sterreich UCB Pharma GmbH
Tel: + 43-(0)1 291 80 Espa a UCB Pharma, S.A.
Tel: + 34 / 91 570 34 Polska UCB Pharma Sp. z o.o. / VEDIM Sp. z o.o. Tel: + 48 22 696 99 France UCB Pharma S.A.
T l: + 33 / (0)1 47 29 44 Portugal UCB Pharma (Produtos Farmac uticos), Lda
Tel: + 351 21 302 5Hrvatska Medis Adria d.o.o.
Tel: +385 (0) 1 230 34 Ireland UCB (Pharma) Ireland Ltd.
Tel: + 353 / (0)1-46 37 Rom nia UCB Pharma Romania S.R.L.
Tel: + 40 21 300 29 Slovenija Medis, d.o.o.
Tel: + 386 1 589 69 sland Vistor hf.
Simi: + 354 535 7Slovensk republika UCB s.r.o., organiza n zlo ka
Tel: + 421 (0) 2 5920 2Italia UCB Pharma S.p.A.
Tel: + 39 / 02 300 Suomi/Finland UCB Pharma Oy Finland
Puh/Tel: + 358 9 2514 4
Lifepharma (Z.A.M.) Ltd
: + 357 22 056Sverige UCB Nordic A/S Tel: + 46 / (0) 40 294 Latvija UCB Pharma Oy Finland
Tel: + 358 9 2514 4221 (Somija)
United Kingdom (Northern Ireland) UCB (Pharma) Ireland Ltd.
Tel : + 353 / (0)1-46 37 This leaflet was last revised in .
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu
Instructions for use
Read all the instructions below before you use Bimzelx pre-filled syringe.
Bimzelx pre-filled syringe at a glance (see Figure A):
Important information:
Do not use this medicine and return it to the pharmacy if:
Needle Cap Syringe Barrel Plunger Rod Needle Finger Grip Plunger Head A For a more comfortable injection: Take the Bimzelx pre-filled syringe(s) out of the refrigerator and let it / them sit on a flat surface at room temperature for 30 to 45 minutes before injecting.
Follow the steps below each time you use Bimzelx.
Step 1: Setting up for your injection(s)
Depending on your prescribed dose, place the following items on a clean flat, well-lit work surface, like a table:
You will also need (not included in the carton):
Step 2: Choose injection site and prepare your injection
2a: Choose your injection site
The places you may choose for your injection are: * your stomach (abdomen) or your thigh (see Figure B). * the back of your arm may also be used if a caregiver is giving you the injection (see Figure C).
Do not inject into areas where the skin is tender, bruised, red, scaly, hard or areas with scars or stretch marks.
Do not inject within 5 cm of the belly-button (navel).
If a second injection is needed for your prescribed dose (320 mg), you should use a different place for your second injection. Do not use the same place to inject twice in a row.
2b: Wash your hands well with soap and water and dry with a clean towel
2c: Prepare your skin
2d: Check the pre-filled syringe (see Figure D)
Step 3: Inject Bimzelx
3a: Remove the pre-filled syringe needle cap
3b: Gently pinch and hold with one hand a fold of skin that you cleaned for the injection. With the other hand, insert the needle into your skin at about 45 degree angle
3c: Firmly push the plunger head all the way down until all the medicine is injected (see Figure G) Expiry Date D E F 45
3d: Lift your thumb off the plunger head (see Figure I). The needle will automatically move back in and lock in place
Step 4: Throw away the used Bimzelx pre-filled syringe
Put the used pre-filled syringe in a sharps disposal container straight away after use (see Figure J).
If you need to have a second injection as prescribed by your doctor, use a new Bimzelx pre-filled syringe and repeat steps 2 to 4. Make sure to select a new injection site for your second injection.
G H I J Package leaflet: Information for the user
Bimzelx 160 mg solution for injection in pre-filled pen bimekizumab
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Entry 1 - fullUrl = Composition/composition-en-28d78e4ecee5ce96f67160a74729d480
Resource Composition:
Generated Narrative: Composition composition-en-28d78e4ecee5ce96f67160a74729d480
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1575/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - bimzelx
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp28d78e4ecee5ce96f67160a74729d480
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp28d78e4ecee5ce96f67160a74729d480
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1575/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Bimzelx 160 mg solution for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en